Answers are grounded in this paper and cite their sources.
BACKGROUND AND AIMS: Tumor plasticity contributes to hepatocellular carcinoma (HCC) progression and therapy resistance, but chromatin mechanisms underlying progenitor-like malignant cell states remain incompletely defined. This study investigates whether ASF1B functions as an oncofetal chromatin regulator of these states in HCC. APPROACH AND RESULTS: Integration of a human hepatocyte differentiation model with clinical and single-cell datasets identifies ASF1B as an oncofetal histone chaperone reactivated in HCC and associated with poor differentiation and unfavorable survival. Functional analyses show that ASF1B promotes progenitor- and stemness-associated properties, favors less-differentiated malignant cell states, and enhances tumor growth, metastatic phenotypes, and sorafenib resistance. Mechanistically, ASF1B interacts with histone H3.3, increases H3.3 enrichment and RNA polymerase II engagement at the SOX9 promoter, and enhances nascent SOX9 transcription, with HIRA contributing to replication-independent H3.3 deposition. ASF1B and H3.3 also exhibit dynamic co-condensation in live cells and a reconstituted system. Genetic epistasis establishes SOX9 as a major downstream effector. Liver-directed ASF1B depletion reduces tumor burden and enhances sorafenib responsiveness in an immunocompetent HCC model. CONCLUSIONS: ASF1B promotes progenitor-like malignant cell states through an H3.3-SOX9 chromatin regulatory axis and represents a candidate therapeutic vulnerability in HCC. ASF1B and H3.3 additionally exhibit dynamic co-condensation, suggesting a possible biophysical feature.
No takes yet. Share an insight, caveat, or question.
Fang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: